



**TABLE OF CONTENTS**

	<u>Page</u>
I. DISPUTED FACTS CONCERNING THE ASSERTED DEVICE PATENTS .....	1
A. The Device Patents-In-Suit .....	1
a. The '044 and '069 Patents .....	1
b. The '864 Patent .....	2
c. Development of the Asserted Device Patents .....	3
B. New Drug Applications (“NDAS”) .....	4
a. Sanofi’s NDA .....	4
b. Lilly’s NDA and BIV 60 KwikPen .....	4
C. Sanofi’s SoloSTAR® Device Practice All Elements of the Asserted Claims .....	6
D. Infringement of the Asserted Device Patents ('044, '069, and '864 Patents) .....	7
■ [REDACTED] Meets the Disputed Claim Limitations of the '044 Patent .....	7
■ [REDACTED] Meets the Disputed Claim Limitations of the '069 Patent .....	20
■ [REDACTED] Meets the Disputed Claim Limitations of the '864 Patent .....	20
E. Validity of the Asserted Device Patents ('044, '069, and '864 Patents) .....	26
a. Obviousness .....	27
F. Prosecution of the Device Patents .....	35
a. '225 Application Family .....	36
b. '866 Application Family .....	36
c. Prioritized Examination .....	37
II. DISPUTED FACTS CONCERNING THE ASSERTED FORMULATION PATENTS .....	37
A. The Formulation Patents-In-Suit .....	37
a. The Asserted Formulation Patents ('652 and '930 Patents) .....	38
B. New Drug Applications (“NDAS”) .....	38
a. Sanofi’s NDA .....	38
b. Lilly’s NDA .....	40

C. Sanofi’s Reformulated Lantus® Product Practices All Elements of the Asserted Claims 43

D. Infringement of the Asserted Formulation Patents (’652 and ’930 Patents) ..... 43

**a.** We believe Lilly will concede that Lilly’s Proposed Insulin Glargine Product  
        Meets Certain Claim Limitations of the ’652 and ’930 Patents.....43

E. Validity of the Asserted Formulation Patents (’652 and ’930 Patents) ..... 57

**a.** Written Description.....57

Pursuant to Local Rule 16.3(c)(4), Plaintiffs Sanofi-Aventis U.S. LLC (“Sanofi U.S.”) and Sanofi-Aventis Deutschland GmbH (“Sanofi GmbH”) (collectively, “Plaintiffs” or “Sanofi”)<sup>1</sup> submit the following issues of fact that remain to be litigated. Sanofi’s identification of the issues of fact that remain to be litigated is based upon its current understanding of the arguments Defendant Eli Lilly and Company (“Eli Lilly”) is likely to make, based on the pleadings, discovery, and expert reports in the action to date. To the extent that Lilly introduces different or additional facts or alleged facts to meet its burden of proof, Sanofi reserves its right to contest such facts or alleged facts, and to present any and all rebuttal evidence in response.

**I. DISPUTED FACTS CONCERNING THE ASSERTED DEVICE PATENTS**

**A. The Device Patents-In-Suit**

1. U.S. Patent No.8,603,044 (“the ’044 Patent”), U.S. Patent No. 8,679,069 (“the ’069 Patent”), and U.S. Patent No. 8,556,864 (“the ’864 Patent”) are referred to herein as the “Asserted Device Patents.” By assignment, Sanofi GmbH owns all right, title, and interest to each of the Asserted Device Patents-in-Suit.

2. Sanofi U.S. is the exclusive licensee of the Asserted Device Patents-in-Suit with exclusive rights, including the rights to sell and offer to sell in the United States the technologies, products, or services claimed by the Patents-in-Suit, further including the right to sue and recover for the infringement of the Patents-in-Suit.

**a. The ’044 and ’069 Patents**

3. United States Patent 8,679,069 (“the ’069 Patent”) is titled “Pen-Type Injector.”

4. United States Patent No. 8,603,044 (“the ’044 Patent”) is titled “Pen-Type Injector.”

---

<sup>1</sup> Plaintiffs refer to Sanofi throughout to refer to the current corporate entities Sanofi-Aventis U.S. LLC and Sanofi-Aventis Deutschland GmbH, as well as their predecessors-in-interest.

5. The '069 Patent received a Patent Term Adjustment of 406 days under 35 U.S.C. § 154(b).

6. On June 4, 2013, U.S Patent Application No. 13/909,649 (which issued as the '044 Patent) was filed as a continuation of U.S. Patent Application No. 12/944,544 (which issued as the '069 Patent).

7. On November 11, 2010, U.S. Application No. 12/944,544 (which issued as the '069 Patent) was filed as a continuation of U.S. Patent Application No. 11/483,546, filed July 11, 2006. U.S. Patent Application No. 11/483,546 issued as U.S. Patent No. 7,918,833 on April 5, 2011.

8. On July 11, 2006, U.S. Patent Application No. 11/483,546 was filed as a continuation of U.S. Patent Application No. 10/790,225.

9. On March 2, 2004 U.S. Patent Application No. 10/790,225 was filed and claimed priority to Great Britain Patent Application No. 0304822.0.

10. On March 3, 2003, GB Patent Application No. 0304822.0 was filed.

**b. The '864 Patent**

11. U.S. Patent No. 8,556,864 (“the '864 Patent”) is titled “Drive Mechanisms Suitable for Use in Drug Delivery Devices.”

12. The '864 Patent received a Patent Term Adjustment of 301 days under 35 U.S.C. § 154(b).

13. On March 30, 2011, U.S. Patent Application No. 13/075,212 (which issued as the '864 Patent) was filed as a continuation of U.S. Patent Application No. 11/520,598.

14. On September 14, 2009, U.S. Patent Application No. 11/520,598 was filed as a continuation of U.S. Patent Application No. 10/790,866.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.